Ucb S A (UCBJF) 79.6500 $UCBJF
Sanofi Misses on Q1 Earnings, Lackluster Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 10:07AM CDT
Sanofi (SNY) reported first quarter 2014 business earnings of 80 cents per American Depositary Share.
Global Nanomedicine Market Forecasts Report 2013-2019
M2 - Tue Apr 29, 3:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/47pbsh/nanomedicine) has announced the addition of the "Nanomedicine Market - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019" report to their offering. The emergence of nanomedicine and the application of nanomaterials in the healthcare industry will bring about groundbreaking improvements to the current therapeutic and diagnostic scenario.Some of the drivers of this market include increasing research funding, rising government support, improved regulatory framework, technological know-how and rising prevalence of chronic diseases such as diabetes, cancers, obesity, kidney disorders, orthopedic diseases and others. The global nanomedicine market is categorized into six segments on the basis of application, namely neurology, cardiovascular, anti-inflammatory, anti-infective, oncology and others. Oncology held majority of the market share in 2012 on account of following factors: - Presence of high number of commercialized nanomedicine products in the market - Improved bioavailability and efficacy of the tumor specific nanomedicine enabling targeted drug delivery - Rise in nanomedicine drug formulations replacing conventional drug formulations in cancer treatment However, the global market for cardiovascular segment is expected to grow at the fastest pace owing to increasing prevalence of cardiovascular diseases demanding drugs with improved efficacy and therapeutic properties. Furthermore, realizing the importance and benefits of nanomedicine, researchers and manufacturers are striving to develop products with improved therapeutic properties in the cardiovascular segment. The North American nanomedicine market held the majority of global market share in 2012 because of the rapidly growing nanomedicine market in the Asia-Pacific, Latin American and African region, presence of large number of patented nanomedicine products and favorable regulatory framework in the region.In addition, the presence of sophisticated healthcare infrastructure supports development of advanced products such as nano probes, nanorobots, monoclonal antibody based immunoassays and nanoparticle based imaging agents for early detection of diseases. However, the Asia-Pacific region is expected to grow at a faster CAGR owing to presence of high unmet healthcare needs, research collaborations and increase in nanomedicine research funding in emerging economies such as China, India and other economies in the region.China is expected to surpass the United States in terms of nanotechnology funding in the near future, which indicates the growth offered by this region. The global nanomedicine market is categorized into the following segments: Application - Neurology - Cardiovascular - Anti-Inflammatory - Anti-Infectives - Oncology - Others Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global Nanomedicine Market Overview Chapter 4 Global Nanomedicine Market, by Applications Chapter 5 Global Nanomedicine Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles - Abbott Laboratories - Celgene Corporation - CombiMatrix Corporation - GE Healthcare - Johnson & Johnson - Mallinckrodt plc. - Merck & Company Inc. - Nanosphere, Inc. - Pfizer Inc. - Sigma-Tau Pharmaceuticals Inc. - Teva Pharmaceutical Industries Ltd. - UCB SA For more information visit http://www.researchandmarkets.com/research/47...nomedicine
UCB Sales Rise in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 3:30PM CDT
UCB (UCBJF) reported sales results for the first quarter of 2014. Revenues rose 9.1% year over year to approximately $1.2 billion.
Regulatory Update from Impax - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 3:55PM CDT
Impax resubmitted a new drug application (NDA) for Rytary for the symptomatic treatment of Parkinson's disease (PD).
Update on Pfizer's OTC Nexium 24HR - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 3:30PM CDT
Pfizer announced that it has received the FDA approval for its OTC version of AstraZeneca's Nexium 24HR.
Bristol Myers Deal Overshadows Q4 loss at Five Prime - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 10:00AM CDT
Amidst the excitement about the Bristol-Myers deal, Five Prime reported its fourth quarter 2013 results.
UCB to Return Tozadenant Rights - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 4:44PM CDT
UCB announced that it will return global rights to tozadenant (SYN115) to Biotie Therapies Corp.
Sanofi, UCB Ink Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 5:10PM CDT
Sanofi entered into an agreement with UCB for the discovery and development of therapies for immune-mediated diseases including gastroenterology and arthritis.
UCB Misses Earnings Ests, Revs In Line - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 12:32PM CST
UCB reported 2013 earnings per share of $2.56, missed the Zacks Consensus Estimate of $2.84.
UCB : CONVENING NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
Thomson Reuters ONE - Fri Feb 21, 2:01AM CST
The shareholders are invited to attend the Extraordinary General Meeting which will be held on Monday, 24 March 2014, at 09:00 am CET at the registered office of UCB SA/NV, Allee de la Recherche 60 - 1070 Brussels, for the purpose of considering the items shown on the agenda set out below.
Worldwide Nanomedicine Market Report 2013-2019: Neurology, Cardiovascular, Anti-inflammatory, Anti-infective & Oncology Applications
M2 - Wed Feb 19, 9:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/4bpxtn/nanomedicine) has announced the addition of the "Nanomedicine Market - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019" report to their offering. This report includes market estimations for the nanomedicine market for the forecast period 2013 - 2019. The market size is represented in terms of USD billion and the market estimates and forecasts are calculated, considering 2012 as the base year. Moreover, market trends and recent developments have been kept into account while forecasting market growth and revenue for the period 2013 - 2019. The overall nanomedicine market is segmented on the basis of application and geography and the market estimations for each of these segments, in terms of USD billion, is provided in this report. The nanomedicine market, by applications is segmented into neurological, cardiovascular, oncology, anti-inflammatory, anti-infective and other markets. The nanomedicine market is also estimated and analyzed on the basis of geographic regions such as North America, Europe, Asia-Pacific and rest of the world. The global trends such as drivers, restraints and opportunities of the global nanomedicine market is detailed in the market overview chapter of this report., with a view on impact of these factors on market growth along the course of the forecast period. The chapter on competitive landscape consists of heat map analysis of the key players operating in the global nanomedicine market. Some of the key players of this market include GE Healthcare, Mallinckrodt plc, Nanosphere Inc., Pfizer Inc., Merck & Co Inc., Celgene Corporation, CombiMatrix Corporation, Abbott Laboratories and others. The role of these market players in the global nanomedicine market is analyzed by profiling them on the basis of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The global nanomedicine market is categorized into the following segments: - Neurology - Cardiovascular - Anti-Inflammatory - Anti-Infectives - Oncology - Others Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global Nanomedicine Market Overview Chapter 4 Global Nanomedicine Market, by Applications Chapter 5 Global Nanomedicine Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles - Abbott Laboratories - Celgene Corporation - CombiMatrix Corporation - GE Healthcare - Johnson & Johnson - Mallinckrodt plc. - Merck & Company Inc. - Nanosphere, Inc. - Pfizer Inc. - Sigma-Tau Pharmaceuticals Inc. - Teva Pharmaceutical Industries Ltd. - UCB SA For more information visit http://www.researchandmarkets.com/research/4b...nomedicine
CHMP Positive on Roche's RoActemra's Subcutaneous Formulation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 23, 9:50AM CST
Roche recently received positive news when the Committee for Medicinal Products for Human Use (CHMP) rendered a positive opinion on the subcutaneous formulation of rheumatoid arthritis (RA) drug RoActemra.
Loss Narrows at Immunomedics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 26, 8:54AM CDT
Immunomedics reported fourth quarter 2013 loss of 9 cents per share.
Good News for RedHill Biopharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 23, 3:10PM CDT
Good news flowed in at RedHill Biopharma when the company received a positive feedback on its RHB-104.
Another Generic Launch at Mylan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 16, 9:50AM CDT
Mylan launched its generic version of Abbott Labs' Trilipix.
New Data on UCB's Cimzia - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 14, 2:48PM CDT
UCB presented new data from the RAPID-PsA study and RAPID-axSpA study on Cimzia at the European League Against Rheumatism (EULAR) Congress.
Update on UCB Lupus Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 13, 8:40PM CDT
UCB recently presented new data on its lupus candidate, epratuzumab, from an open-label extension study of the EMBLEM phase IIb study
Sanofi Misses on Q1 Earnings, Lackluster Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 10:07AM CDT
Sanofi (SNY) reported first quarter 2014 business earnings of 80 cents per American Depositary Share.
Global Nanomedicine Market Forecasts Report 2013-2019
M2 - Tue Apr 29, 3:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/47pbsh/nanomedicine) has announced the addition of the "Nanomedicine Market - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019" report to their offering. The emergence of nanomedicine and the application of nanomaterials in the healthcare industry will bring about groundbreaking improvements to the current therapeutic and diagnostic scenario.Some of the drivers of this market include increasing research funding, rising government support, improved regulatory framework, technological know-how and rising prevalence of chronic diseases such as diabetes, cancers, obesity, kidney disorders, orthopedic diseases and others. The global nanomedicine market is categorized into six segments on the basis of application, namely neurology, cardiovascular, anti-inflammatory, anti-infective, oncology and others. Oncology held majority of the market share in 2012 on account of following factors: - Presence of high number of commercialized nanomedicine products in the market - Improved bioavailability and efficacy of the tumor specific nanomedicine enabling targeted drug delivery - Rise in nanomedicine drug formulations replacing conventional drug formulations in cancer treatment However, the global market for cardiovascular segment is expected to grow at the fastest pace owing to increasing prevalence of cardiovascular diseases demanding drugs with improved efficacy and therapeutic properties. Furthermore, realizing the importance and benefits of nanomedicine, researchers and manufacturers are striving to develop products with improved therapeutic properties in the cardiovascular segment. The North American nanomedicine market held the majority of global market share in 2012 because of the rapidly growing nanomedicine market in the Asia-Pacific, Latin American and African region, presence of large number of patented nanomedicine products and favorable regulatory framework in the region.In addition, the presence of sophisticated healthcare infrastructure supports development of advanced products such as nano probes, nanorobots, monoclonal antibody based immunoassays and nanoparticle based imaging agents for early detection of diseases. However, the Asia-Pacific region is expected to grow at a faster CAGR owing to presence of high unmet healthcare needs, research collaborations and increase in nanomedicine research funding in emerging economies such as China, India and other economies in the region.China is expected to surpass the United States in terms of nanotechnology funding in the near future, which indicates the growth offered by this region. The global nanomedicine market is categorized into the following segments: Application - Neurology - Cardiovascular - Anti-Inflammatory - Anti-Infectives - Oncology - Others Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global Nanomedicine Market Overview Chapter 4 Global Nanomedicine Market, by Applications Chapter 5 Global Nanomedicine Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles - Abbott Laboratories - Celgene Corporation - CombiMatrix Corporation - GE Healthcare - Johnson & Johnson - Mallinckrodt plc. - Merck & Company Inc. - Nanosphere, Inc. - Pfizer Inc. - Sigma-Tau Pharmaceuticals Inc. - Teva Pharmaceutical Industries Ltd. - UCB SA For more information visit http://www.researchandmarkets.com/research/47...nomedicine
UCB Sales Rise in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 3:30PM CDT
UCB (UCBJF) reported sales results for the first quarter of 2014. Revenues rose 9.1% year over year to approximately $1.2 billion.
Regulatory Update from Impax - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 3:55PM CDT
Impax resubmitted a new drug application (NDA) for Rytary for the symptomatic treatment of Parkinson's disease (PD).
Update on Pfizer's OTC Nexium 24HR - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 3:30PM CDT
Pfizer announced that it has received the FDA approval for its OTC version of AstraZeneca's Nexium 24HR.
Bristol Myers Deal Overshadows Q4 loss at Five Prime - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 10:00AM CDT
Amidst the excitement about the Bristol-Myers deal, Five Prime reported its fourth quarter 2013 results.
UCB to Return Tozadenant Rights - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 4:44PM CDT
UCB announced that it will return global rights to tozadenant (SYN115) to Biotie Therapies Corp.
Sanofi, UCB Ink Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 5:10PM CDT
Sanofi entered into an agreement with UCB for the discovery and development of therapies for immune-mediated diseases including gastroenterology and arthritis.
UCB Misses Earnings Ests, Revs In Line - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 12:32PM CST
UCB reported 2013 earnings per share of $2.56, missed the Zacks Consensus Estimate of $2.84.
UCB : CONVENING NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
Thomson Reuters ONE - Fri Feb 21, 2:01AM CST
The shareholders are invited to attend the Extraordinary General Meeting which will be held on Monday, 24 March 2014, at 09:00 am CET at the registered office of UCB SA/NV, Allee de la Recherche 60 - 1070 Brussels, for the purpose of considering the items shown on the agenda set out below.
Worldwide Nanomedicine Market Report 2013-2019: Neurology, Cardiovascular, Anti-inflammatory, Anti-infective & Oncology Applications
M2 - Wed Feb 19, 9:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/4bpxtn/nanomedicine) has announced the addition of the "Nanomedicine Market - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019" report to their offering. This report includes market estimations for the nanomedicine market for the forecast period 2013 - 2019. The market size is represented in terms of USD billion and the market estimates and forecasts are calculated, considering 2012 as the base year. Moreover, market trends and recent developments have been kept into account while forecasting market growth and revenue for the period 2013 - 2019. The overall nanomedicine market is segmented on the basis of application and geography and the market estimations for each of these segments, in terms of USD billion, is provided in this report. The nanomedicine market, by applications is segmented into neurological, cardiovascular, oncology, anti-inflammatory, anti-infective and other markets. The nanomedicine market is also estimated and analyzed on the basis of geographic regions such as North America, Europe, Asia-Pacific and rest of the world. The global trends such as drivers, restraints and opportunities of the global nanomedicine market is detailed in the market overview chapter of this report., with a view on impact of these factors on market growth along the course of the forecast period. The chapter on competitive landscape consists of heat map analysis of the key players operating in the global nanomedicine market. Some of the key players of this market include GE Healthcare, Mallinckrodt plc, Nanosphere Inc., Pfizer Inc., Merck & Co Inc., Celgene Corporation, CombiMatrix Corporation, Abbott Laboratories and others. The role of these market players in the global nanomedicine market is analyzed by profiling them on the basis of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The global nanomedicine market is categorized into the following segments: - Neurology - Cardiovascular - Anti-Inflammatory - Anti-Infectives - Oncology - Others Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global Nanomedicine Market Overview Chapter 4 Global Nanomedicine Market, by Applications Chapter 5 Global Nanomedicine Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles - Abbott Laboratories - Celgene Corporation - CombiMatrix Corporation - GE Healthcare - Johnson & Johnson - Mallinckrodt plc. - Merck & Company Inc. - Nanosphere, Inc. - Pfizer Inc. - Sigma-Tau Pharmaceuticals Inc. - Teva Pharmaceutical Industries Ltd. - UCB SA For more information visit http://www.researchandmarkets.com/research/4b...nomedicine
CHMP Positive on Roche's RoActemra's Subcutaneous Formulation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 23, 9:50AM CST
Roche recently received positive news when the Committee for Medicinal Products for Human Use (CHMP) rendered a positive opinion on the subcutaneous formulation of rheumatoid arthritis (RA) drug RoActemra.
Loss Narrows at Immunomedics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 26, 8:54AM CDT
Immunomedics reported fourth quarter 2013 loss of 9 cents per share.
Good News for RedHill Biopharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 23, 3:10PM CDT
Good news flowed in at RedHill Biopharma when the company received a positive feedback on its RHB-104.
Another Generic Launch at Mylan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 16, 9:50AM CDT
Mylan launched its generic version of Abbott Labs' Trilipix.
New Data on UCB's Cimzia - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 14, 2:48PM CDT
UCB presented new data from the RAPID-PsA study and RAPID-axSpA study on Cimzia at the European League Against Rheumatism (EULAR) Congress.
Update on UCB Lupus Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 13, 8:40PM CDT
UCB recently presented new data on its lupus candidate, epratuzumab, from an open-label extension study of the EMBLEM phase IIb study
